estrogen receptor
Concr Exploring Biomarkers of Response to Neoadjuvant TNBC Therapy
The firm will use its AI-based platform to create "digital twins" of TNBC patients and predict neoadjuvant treatment response.
The firm is seeing the fruit of a two-year investment in transitioning from a research lab to a clinical focus.
Sermonix Pharma Using Guardant Health CDx to Screen Breast Cancer Patients for Lasofoxifene Trial
The ELAINE-3 study, a Phase III trial, will use the Guardant360 CDx liquid biopsy test to screen patients for ESR1 mutations.
Breast Cancer Outcomes Show Ties to Neighborhood Income in New Study
In estrogen receptor-positive breast cancer patients, lower income appeared to track with higher tumor expression-based recurrence scores, and shorter survival in the low-risk RS group.
OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
Jun 13, 2019
Jun 5, 2018